Format

Send to

Choose Destination
Am J Kidney Dis. 2019 Jan;73(1):112-118. doi: 10.1053/j.ajkd.2018.02.352. Epub 2018 Apr 25.

Kidney Transplantation in HIV-Positive Patients: A Single-Center, 16-Year Experience.

Author information

1
Department of Surgery, Drexel University, Philadelphia, PA.
2
Department of Medicine, Drexel University, Philadelphia, PA.
3
USU-Walter Reed Department of Surgery, Uniformed Services University, Bethesda, MD. Electronic address: jindalr@msn.com.
4
Astellas Pharmaceuticals, Northbrook, IL.
5
Department of Medicine, Drexel University, Philadelphia, PA. Electronic address: AD3NB@hscmail.mcc.virginia.edu.

Abstract

Hahnemann University Hospital has performed 120 kidney transplantations in human immunodeficiency virus (HIV)-positive individuals during the last 16 years. Our patient population represents ∼10% of the entire US population of HIV-positive kidney recipients. In our earlier years of HIV transplantation, we noted increased rejection rates, often leading to graft failure. We have established a multidisciplinary team and over the years have made substantial protocol modifications based on lessons learned. These modifications affected our approach to candidate evaluation, donor selection, perioperative immunosuppression, and posttransplantation monitoring and resulted in excellent posttransplantation outcomes, including 100% patient and graft survival at 1 year and patient and graft survival at 3 years of 100% and 96%, respectively. We present key clinical data, including a granular patient-level analysis of the associations of antiretroviral therapy regimens with long-term survival, cellular and antibody-mediated rejection rates, and the causes of allograft failures. In summary, we provide details on the evolution of our approach to HIV transplantation during the last 16 years, including strategies that may improve outcomes among HIV-positive kidney transplantation candidates throughout the United States.

KEYWORDS:

HIV Organ Policy Equity (HOPE); HIV-positive donor; HIV-positive recipient; Human immunodeficiency virus (HIV); allograft survival; antiretroviral therapy (ART); belatacept; donor selection; end-stage renal disease (ESRD); immunosuppression; kidney transplantation; review

PMID:
29705074
DOI:
10.1053/j.ajkd.2018.02.352

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center